{ "id": "SQ-LIP-000042", "question": "How does lipedema affect mental health (depression and anxiety)?", "question_pt": "Como o lipedema afeta a saúde mental (depressão e ansiedade)?", "phrasings": [], "phrasings_pt": [], "knowledge_state": "emerging", "tags": [ "Mental health", "Comorbidities" ], "keywords": [ "depression", "anxiety", "mental health", "lipedema" ], "current_answer": "Based on currently indexed evidence, lipedema is consistently associated with elevated depressive and anxiety symptoms and substantially reduced quality of life, though the evidence base is dominated by cross-sectional surveys (low GRADE) with two moderate-quality syntheses. A 2025 meta-analysis (moderate GRADE) found women with lipedema have reduced HRQoL across all SF-36/RAND-36 domains versus population norms, including impaired emotional well-being reflecting frequent anxiety/depression, but with high heterogeneity (I²=83–93%). A moderate-quality Swiss cohort (n=239) found anxiety in 64.4% and depression in 23.4% (HADS≥8). Across many low-quality cross-sectional studies, depression prevalence/symptom rates vary widely (self-reported ~13.5%–48%; PHQ-9 ≥10 in roughly 50–59% in several samples), and case-control studies report higher depression (43.6% vs 18.5%) and anxiety than BMI/age-matched controls. Depression severity correlates strongly and inversely with quality of life (r up to −0.775) and positively with pain, disease duration, and disease stage in several studies. IMPORTANTLY, the association is not uniform: one BMI-adjusted comparison (low GRADE) found NO significant difference in depression or anxiety between lipedema and overweight/obese women despite worse disability, and Swiss data found psychosocial burden did not differ by disease stage — suggesting comorbid obesity, pain, stigma, and disability may drive much of the mood burden rather than lipedema per se. A small case-control study reported anxiety and emotion-regulation deficits persisting after BMI adjustment. Two uncontrolled liposuction series (low GRADE) report post-operative reductions in depression/anxiety scores and improved QoL, but these are symptomatic/psychosocial improvements without controlled or disease-course evidence. Overall: an association is well-documented but causal direction, the independent contribution of lipedema beyond obesity/pain, and clinical diagnosis rates (versus self-report symptom screens) remain uncertain.", "current_answer_pt": "Com base nas evidências atualmente indexadas, o lipedema está consistentemente associado a sintomas elevados de depressão e ansiedade e a qualidade de vida substancialmente reduzida, embora a base de evidências seja dominada por estudos transversais (GRADE baixo), com duas sínteses de qualidade moderada. Uma metanálise de 2025 (GRADE moderado) encontrou redução da QVRS em todos os domínios do SF-36/RAND-36 versus normas populacionais, incluindo bem-estar emocional prejudicado refletindo ansiedade/depressão frequentes, mas com alta heterogeneidade (I²=83–93%). Uma coorte suíça de qualidade moderada (n=239) encontrou ansiedade em 64,4% e depressão em 23,4% (HADS≥8). Em muitos estudos transversais de baixa qualidade, a prevalência/taxas de sintomas de depressão variam amplamente (autorrelato ~13,5%–48%; PHQ-9 ≥10 em cerca de 50–59% em várias amostras), e estudos caso-controle relatam maior depressão (43,6% vs 18,5%) e ansiedade do que controles pareados por IMC/idade. A gravidade da depressão correlaciona-se forte e inversamente com a qualidade de vida (r até −0,775) e positivamente com dor, duração e estágio da doença em vários estudos. IMPORTANTE: a associação não é uniforme: uma comparação ajustada por IMC (GRADE baixo) NÃO encontrou diferença significativa em depressão ou ansiedade entre mulheres com lipedema e com sobrepeso/obesidade, apesar de pior incapacidade, e dados suíços não encontraram diferença do encargo psicossocial por estágio da doença — sugerindo que obesidade comórbida, dor, estigma e incapacidade podem impulsionar grande parte do encargo de humor, em vez do lipedema em si. Um pequeno estudo caso-controle relatou ansiedade e déficits de regulação emocional persistindo após ajuste por IMC. Duas séries não controladas de lipoaspiração (GRADE baixo) relatam reduções pós-operatórias nos escores de depressão/ansiedade e melhora da QV, mas estas são melhoras sintomáticas/psicossociais sem evidência controlada ou de curso da doença. No geral: a associação está bem documentada, mas a direção causal, a contribuição independente do lipedema além da obesidade/dor e as taxas de diagnóstico clínico (versus triagens de sintomas autorrelatadas) permanecem incertas.", "bottom_line": "Women with lipedema consistently report higher rates of depression and anxiety and worse emotional quality of life compared to general population norms, with one meta-analysis and multiple surveys confirming this pattern. Whether lipedema itself drives this burden — or whether it is largely explained by comorbid obesity, chronic pain, and stigma — remains unresolved, and nearly all studies are cross-sectional snapshots that cannot establish cause and effect.", "bottom_line_pt": "Mulheres com lipedema relatam consistentemente taxas mais altas de depressão e ansiedade e pior qualidade de vida emocional em comparação com a população geral, padrão confirmado por uma metanálise e múltiplos estudos. Se é o lipedema em si que causa esse sofrimento — ou se ele é explicado principalmente pela obesidade associada, dor crônica e estigma — permanece sem resposta, e quase todos os estudos são transversais, não permitindo estabelecer causa e efeito.", "major_uncertainty": "Whether lipedema independently elevates depression/anxiety beyond the effects of comorbid obesity, chronic pain, and stigma remains unresolved: the strongest within-design comparison (BMI-matched overweight/obese controls) found no mood difference, while case-control versus general population shows clear differences. Nearly all evidence is cross-sectional, precluding causal direction, and prevalence estimates vary enormously by instrument (self-report vs validated screen vs clinical diagnosis).", "version": "1.1", "created": "2026-06-02", "updated": "2026-06-02", "compiled_by": { "model": "anthropic/claude-opus-4.8", "label": "Claude Opus 4.8", "date": "2026-06-02" }, "outcomes": [ { "outcome": "Depression (association with lipedema)", "outcome_pt": "Depressão (associação com lipedema)", "direction": "increased", "confidence": "low", "disease_modifying": false, "note": "Elevated symptoms vs general population; one BMI-matched study found no excess vs obese controls.", "note_pt": "Sintomas elevados vs população geral; um estudo pareado por IMC não achou excesso vs obesos." }, { "outcome": "Anxiety (association with lipedema)", "outcome_pt": "Ansiedade (associação com lipedema)", "direction": "increased", "confidence": "low", "disease_modifying": false, "note": "High anxiety rates (HADS up to 64%); some persists after BMI adjustment in small studies.", "note_pt": "Altas taxas de ansiedade (HADS até 64%); parte persiste após ajuste por IMC em pequenos estudos." }, { "outcome": "Quality of life", "outcome_pt": "Qualidade de vida", "direction": "reduced", "confidence": "moderate", "disease_modifying": false, "note": "Meta-analysis: reduced HRQoL across all SF-36/RAND-36 domains vs norms; correlates with depression.", "note_pt": "Metanálise: QVRS reduzida em todos os domínios SF-36/RAND-36 vs normas; correlaciona-se com depressão." }, { "outcome": "Mood/QoL after liposuction", "outcome_pt": "Humor/QV após lipoaspiração", "direction": "improved", "confidence": "very_low", "disease_modifying": false, "note": "Uncontrolled series show post-op drops in depression/anxiety scores; symptomatic, not disease-modifying.", "note_pt": "Séries não controladas mostram quedas pós-op em escores de depressão/ansiedade; sintomático, não modifica doença." } ], "evidence_direction": { "supporting": 19, "contradicting": 0, "other": 1 }, "knowledge_freshness": { "pct": 82, "sources": 22, "newest": 2025, "oldest": 2016, "small_base": false, "label": "current evidence base" }, "claims": [ { "id": "SCR-LIP-000167", "role": "supporting", "statement": "In a cross-sectional study of 43 Czech women with lipedema, 50.9% had moderate-to-severe depressive symptoms (PHQ-9 >=10) and WHOQOL-BREF scores were low across domains (psychological 46.3, physical 50.8), with the psychological domain most affected; specific physical symptoms (shortness of breath, muscle stiffness, appetite problems, fatigue, numbness) were significantly associated with depression severity." }, { "id": "SCR-LIP-000168", "role": "supporting", "statement": "In a cross-sectional study of 354 women with lipedema, 35% met FMS criteria, and those with comorbid FMS had significantly higher anxiety (13.11 vs 9.87) and depression (10.23 vs 8.26) scores and lower SF-12 physical (35.37 vs 42.55) and mental (35.27 vs 40.38) quality-of-life scores (all p<0.001)." }, { "id": "SCR-LIP-000169", "role": "supporting", "statement": "In a study comparing lipedema patients with population controls matched for sex, age and BMI, lipedema patients reported worse self-rated general health, higher rates of self-reported depression (43.6% vs 18.5%, p=0.001) with PHQ-8 depressive symptoms in 89.7% versus 39.3% of controls, more severe pain and pain-related disability, fewer close social contacts, and a strong positive correlation between pain severity and depressive symptoms (rho=0.612, p<0.001)." }, { "id": "SCR-LIP-000170", "role": "supporting", "statement": "In a survey of 98 Polish women with lipedema, all WHOQOL-BREF domains scored below general-population values (physical health 45.4, psychological 46.3, social relationships 50.4, environment 49.6 on 0-100), 59.2% had PHQ-9 scores >=10 indicating possible depression (mean PHQ-9 12.2), and core lipedema symptoms (Factor 1: leg heaviness, joint/tissue/muscle pain, swelling, stiffness) were the only significant predictor of worse quality of life (beta=-0.345, p=0.004, model explaining 23.5% of variance)." }, { "id": "SCR-LIP-000171", "role": "supporting", "statement": "In this scoping review, lipedema patients showed reduced quality of life (EQ-5D-3L 66.1 vs 85 in the Dutch population; WHOQOL-BREF physical/mental domains below midpoint), depression prevalence of 22.7%-42%, 51.1% with mental disorders, and QoL strongly correlated with depression severity (r=-0.75)." }, { "id": "SCR-LIP-000172", "role": "supporting", "statement": "In an observational study of 26 females with lipedema versus healthy controls, lipedema patients showed markedly higher emotion regulation difficulties (DERS total 135.69±13.12 vs 53.00±9.03) and anxiety (HAM-A 27.62±8.98 vs 4.96±2.51), with all group differences remaining significant after adjusting for BMI via ANCOVA (DERS total F(1,49)=582.95, p<0.001; HAM-A F(1,49)=123.10, p<0.001)." }, { "id": "SCR-LIP-000173", "role": "supporting", "statement": "In 329 women with lipedema, lower quality of life (WHOQOL-BREF) was independently predicted by higher depression (PHQ-9 β=-0.36), higher appearance-related distress (DAS-24 β=-0.29), lower mobility (β=0.27) and higher symptom severity, with the final regression model explaining 73% of QoL variance and mean PHQ-9 of 11.87 indicating minor depression." }, { "id": "SCR-LIP-000174", "role": "supporting", "statement": "In a cross-sectional survey of 245 women with lipedema, health-related stigma was significantly higher than in an age-matched general female population (Distress 49.5 vs 17.1–28.7; 65% with moderate/severe distress) and correlated negatively with all RAND-36 quality-of-life domains (strongest for social functioning r=−0.54 and emotional well-being r=−0.50), while greater perceived social support correlated positively with HRQoL." }, { "id": "SCR-LIP-000175", "role": "supporting", "statement": "In a cross-sectional study of 37 women with lipedema versus 36 with lymphedema, lipedema patients showed moderate depression (PHQ-9 mean 10.4) and impaired global quality of life (LYMQOL-Leg 5.47) comparable to lymphedema patients, while lymphedema patients had worse functional status and life satisfaction; in lipedema, longer disease duration correlated with PHQ-9 (r=-0.415, p=0.028) and BMI correlated with functional impairment." }, { "id": "SCR-LIP-000176", "role": "supporting", "statement": "In a cross-sectional cohort of 40 lipedema patients, 87.5% showed severe/high depression risk (mean HAM-D 25.39) and 92.5% showed severe/high anxiety risk (mean HAM-A 23.45), with serum vitamin D inversely correlated with depression (adjusted r=-0.580, p<0.001) and anxiety (adjusted r=-0.489, p=0.002), and BMI positively correlated with both depression (r=0.560) and anxiety (r=0.511)." }, { "id": "SCR-LIP-000177", "role": "refines", "statement": "Compared with overweight/obese women, women with lipedema showed greater disability (WHO-DAS II domains for mobility, household activities, and social participation remained significantly worse after robust BMI adjustment, e.g. social participation Z=3.15, p=0.002; days with difficulties Z=4.13, p<0.001), but showed NO significant differences in depression (BDI-II median 11 vs 8, p=0.130; HADS-D p=0.474) or anxiety (HADS-A 9.16 vs 8.10, p=0.162), before or after BMI adjustment." }, { "id": "SCR-LIP-000349", "role": "supporting", "statement": "In a survey of lipedema patients comparing self-reported stages, more advanced stage (3-4) was associated with higher rates of depression (48.3% vs 34.8%, p<0.001), social isolation (staying home 64.3% vs 44.4%), life dissatisfaction (35.7% vs 22.0%), and loss of mobility, while psychological burden such as inferiority complex (72.8%) and constantly thinking about lipedema (73.4%) was high across all stages." }, { "id": "SCR-LIP-000350", "role": "supporting", "statement": "This narrative review synthesizing 25 references reports that lipedema patients show greater emotional dysregulation and higher anxiety (Al-Wardat: 26 patients vs 26 controls via DERS/HAM-A), significant behavioral disturbances versus overweight/obese controls (Chachaj et al.), depressive/anxious symptoms associated with comorbid fibromialgia (Cagliyan Turk et al.), occupational limitations in 51–73% of respondents (Clarke et al.), and that liposuction significantly reduced depressive symptoms and improved quality of life and body image (Arndt et al.)." }, { "id": "SCR-LIP-000351", "role": "supporting", "statement": "In a systematic review and meta-analysis of cross-sectional cohorts, women with lipedema showed reduced HRQoL across all SF-36/RAND-36 domains versus population norms, with the largest deficits in energy/fatigue (43.50 vs 59.4), bodily pain (51.77 vs 77.4), role physical (51.10 vs 82.4), and general health (49.64 vs 73.1), plus impaired emotional well-being (64.19 vs 73.2) reflecting frequent anxiety/depression." }, { "id": "SCR-LIP-000352", "role": "supporting", "statement": "In a prospective study of lipedema patients undergoing power-assisted liposuction, PHQ-4 total scores fell from 4.47 (mild depression, above population norm) to 2.10 (p<0.001), with anxiety subscale dropping 2.47→0.93 and depression subscale 2.00→1.17, while quality-of-life satisfaction (FLZM health module 45.77→88.00), self-esteem (RSES 29.93→33.33), and emotional stability all improved significantly postoperatively." }, { "id": "SCR-LIP-000353", "role": "supporting", "statement": "In a cross-sectional survey of women with lipedema (n=112), WHOQOL-BREF averaged 3.12 (1-5 scale) and life satisfaction (SWLS) averaged 3.63 (below midpoint), with symptom severity explaining 13.9% of QoL variance; psychological flexibility (AAQ-II β=0.26) and social connectedness (SCS-R β=0.37) independently predicted QoL after controlling for symptom severity, raising explained variance to 44.4%." }, { "id": "SCR-LIP-000354", "role": "supporting", "statement": "In a national Swedish survey of women with lipedema, RAND-36 scores were 25-35 points below the age-matched general female population across all subscales (largest gap in physical role functioning, ~43 points lower in ages 60-79; smallest in emotional well-being, ~10 points), with worse physical and social functioning at higher lipedema stages and a self-reported depression prevalence of 13.5%." }, { "id": "SCR-LIP-000355", "role": "supporting", "statement": "In 511 lipedema patients, PHQ-9 averaged 10.84±6.39 with 54% at risk of moderate-to-severe depression, WHOQOL-BREF global score averaged 60.5±16.02 (lowest in physical 54.54 and psychological 51.91 domains), and quality-of-life impairment correlated with disease stage (r=0.55, p<0.001) and inversely with depression score (r=-0.775, p<0.0001)." }, { "id": "SCR-LIP-000356", "role": "supporting", "statement": "In a survey of lipedema patients, RAND-36 quality of life was significantly lower than the general Dutch female population (59.3 vs 74.9, p<0.001) and EQ-5D-3L was reduced (66.1 vs 85), with 42.0% reporting anxiety/depression and 74.1% reporting pain/discomfort (vs 31.1% in the general population)." }, { "id": "SCR-LIP-000357", "role": "supporting", "statement": "In a Swiss cohort of 239 lipedema patients assessed with validated questionnaires, 64.4% had anxiety (HADS≥8), 23.4% had depression (HADS≥8), and low quality of life was found in 71.5% (PCS-SF36) and 67.4% (MCS-SF36), with none of these psychosocial parameters differing significantly across disease stages (p>0.5)." } ], "references": [ "DOI:10.3389/fgwh.2025.1629077", "DOI:10.1089/lrb.2023.0038", "DOI:10.3390/life14030295", "DOI:10.1186/s12905-021-01174-y", "DOI:10.3390/ijerph181910223", "DOI:10.1007/s40519-019-00703-x", "DOI:10.3390/ijerph192013679", "DOI:10.1080/13548506.2018.1459750", "DOI:10.1080/07399332.2025.2499487", "DOI:10.1089/lrb.2024.0117", "DOI:10.1515/hmbci-2021-0027", "DOI:10.17219/acem/181146", "DOI:10.1007/s11136-022-03216-w", "DOI:10.12740/app/201427", "DOI:10.1177/02683555251410009", "DOI:10.1016/j.bjps.2024.02.048", "DOI:10.1007/s11136-015-1080-x", "DOI:10.1186/s12905-022-02022-3", "DOI:10.3390/jcm11102836", "DOI:10.21203/rs.3.rs-2705753/v1", "DOI:10.1007/s13555-018-0241-6", "DOI:10.1371/journal.pone.0319099" ], "cite": "Scientific Claim Registry. How does lipedema affect mental health (depression and anxiety)?. SQ-LIP-000042 v1.1; 2026-06-02. https://scientificclaims.org/q/SQ-LIP-000042/v1.1.html", "versions": [ { "version": "1.1", "date": "2026-06-02", "url": "https://scientificclaims.org/q/SQ-LIP-000042/v1.1.html" }, { "version": "1.0", "date": "2026-06-02", "url": "https://scientificclaims.org/q/SQ-LIP-000042/v1.0.html" } ], "url": "https://scientificclaims.org/q/SQ-LIP-000042.html", "url_pt": "https://scientificclaims.org/pt/q/SQ-LIP-000042.html", "version_url": "https://scientificclaims.org/q/SQ-LIP-000042/v1.1.html", "license": "CC-BY-4.0", "disclaimer": "Evidence-bounded summary; not medical advice." }